Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

(Bayer Study ONC-2013-036) A Phase II Single-Arm Study of Regorafenib Maintenance Therapy in Patients With T3, T4 or Node-Positive Rectal Cancer Patients Who Completed Curative-Intent Treatment

NCT02287727 is registered in ClinicalTrials.gov with Roswell Park Cancer Institute as lead sponsor.

NCT NCT02287727
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02287727 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
(Bayer Study ONC-2013-036) A Phase II Single-Arm Study of Regorafenib Maintenance Therapy in Patients With T3, T4 or Node-Positive Rectal Cancer Patients Who Completed Curative-Intent Treatment
Lead sponsor
Roswell Park Cancer Institute
Phase
Phase 2
Overall status
Withdrawn
Start date
March 31, 2015
Completion date
Not reported
Enrollment
0 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

rectal adenocarcinoma, stage iia rectal cancer, stage iib rectal cancer, stage iic rectal cancer, stage iiia rectal cancer, stage iiib rectal cancer